Skip to main content
Figure 8 | Journal of Neuroinflammation

Figure 8

From: 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) attenuates the expression of LPS- and Aβ peptide-induced inflammatory mediators in astroglia

Figure 8

AICAR inhibits LPS-and Aβ-induced activation of Pkb/Akt kinase activity, but activates AMP kinase activity, in astrocyte-enriched glial cell cultures. Cultures pretreated with AICAR or untreated cells were stimulated with LPS (0.125 μg/ml) and 7.5 μM Aβ for the indicated time periods following which cell homogenates were western-immunoblotted for phosphorylated forms of AMPK and Pkb/Akt. Figure 8A shows immunoblots for p-Pkb/Akt proteins. Samples (1 and 7) correspond to control, (2 and 8), (3 and 9), (4 and 10), (5 and 11), (6 and 12) correspond to cells treated with LPS + Aβ +/- 1 mM AICAR for 15 min, 30 min, 45 min, 4 h or 12 h respectively (as shown). Figure B shows phosphor-AMP K (Thr-172 of the α12 subunits) and Figure C to phosphorylated AMPK (Ser 108) of AMPK β subunit. In Figures B and C samples (1) control (2 and 5), (3 and 6) and (4 and 7) correspond to cells treated with LPS + Aβ peptide (for 15 min, 30 min or 60 min respectively) with or without AICAR pre-treatment. Fig D, shows AICAR-mediated inhibition of TNF-α/IL-1β- and Aβ-induced activation of ERK and activation of AMPK. Cells were pre-incubated with AICAR (1 mM) for 4 h prior to treatment with cytokine and Aβ (25–35). Cell homogenates were prepared at indicated time points and western immunoblotted for either phosphorylated or nonphosphorylated iso forms as shown.

Back to article page